{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T01:49:39Z","timestamp":1768614579711,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,13]]},"DOI":"10.7759\/cureus.24117","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T20:14:27Z","timestamp":1649880867000},"source":"Crossref","is-referenced-by-count":5,"title":["Osteoporosis Prevention and Treatment: The Risk of Comorbid Cardiovascular Events in Postmenopausal Women"],"prefix":"10.7759","author":[{"given":"Zachary  A","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avia","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian A","family":"Leibowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc M","family":"Kesselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-017-0316-5","article-title":"Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States","volume":"12","author":"Durden E","year":"2017","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos. 2017, 12:22. 10.1007\/s11657-017-0316-5","journal-title":"Arch Osteoporos"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011524","article-title":"Factors related with osteoporosis treatment in postmenopausal women","volume":"97","author":"Rossi LM","year":"2018","unstructured":"Rossi LM, Copes RM, Dal Osto LC, Flores C, Comim FV, Premaor MO. Factors related with osteoporosis treatment in postmenopausal women. Medicine (Baltimore). 2018, 97:e11524. 10.1097\/MD.0000000000011524","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1602599","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black DM","year":"2016","unstructured":"Black DM, Rosen CJ. Postmenopausal osteoporosis. N Engl J Med. 2016, 374:2095-6. 10.1056\/NEJMc1602599","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2016.09.022","article-title":"Osteoporosis and ischemic cardiovascular disease","volume":"84","author":"Laroche M","year":"2017","unstructured":"Laroche M, P\u00e9courneau V, Blain H, et al.. Osteoporosis and ischemic cardiovascular disease. Joint Bone Spine. 2017, 84:427-32. 10.1016\/j.jbspin.2016.09.022","journal-title":"Joint Bone Spine"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/bonekey.2012.144","article-title":"Association between cardiovascular diseases and osteoporosis-reappraisal","volume":"1","author":"Szulc P","year":"2012","unstructured":"Szulc P. Association between cardiovascular diseases and osteoporosis-reappraisal. Bonekey Rep. 2012, 1:144. 10.1038\/bonekey.2012.144","journal-title":"Bonekey Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2174\/1570161117666190408165805","article-title":"Calcium and vitamin D supplementation. Myths and realities with regard to cardiovascular risk","volume":"17","author":"Muscogiuri G","year":"2019","unstructured":"Muscogiuri G, Barrea L, Altieri B, et al.. Calcium and vitamin D supplementation. Myths and realities with regard to cardiovascular risk. Curr Vasc Pharmacol. 2019, 17:610-7. 10.2174\/1570161117666190408165805","journal-title":"Curr Vasc Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3691","article-title":"Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis","volume":"341","author":"Bolland MJ","year":"2010","unstructured":"Bolland MJ, Avenell A, Baron JA, et al.. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010, 341:c3691. 10.1136\/bmj.c3691","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2021.03.009","article-title":"Postmenopausal osteoporosis: latest guidelines","volume":"50","author":"Arceo-Mendoza RM","year":"2021","unstructured":"Arceo-Mendoza RM, Camacho PM. Postmenopausal osteoporosis: latest guidelines. Endocrinol Metab Clin North Am. 2021, 50:167-78. 10.1016\/j.ecl.2021.03.009","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3069","article-title":"Sclerostin is expressed in the atherosclerotic plaques of patients who undergoing carotid endarterectomy","volume":"35","author":"Leto G","year":"2019","unstructured":"Leto G, D'Onofrio L, Lucantoni F, et al.. Sclerostin is expressed in the atherosclerotic plaques of patients who undergoing carotid endarterectomy. Diabetes Metab Res Rev. 2019, 35:e3069. 10.1002\/dmrr.3069","journal-title":"Diabetes Metab Res Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0158","article-title":"Romosozumab in the treatment of osteoporosis","volume":"12","author":"Kobza AO","year":"2020","unstructured":"Kobza AO, Papaioannou A, Lau AN, Adachi JD. Romosozumab in the treatment of osteoporosis. Immunotherapy. 2020, 12:965-81. 10.2217\/imt-2020-0158","journal-title":"Immunotherapy"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X17726744","article-title":"Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential","volume":"9","author":"McClung MR","year":"2017","unstructured":"McClung MR. Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential. Ther Adv Musculoskelet Dis. 2017, 9:263-70. 10.1177\/1759720X17726744","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2012.4035","article-title":"Body fat distribution after menopause and cardiovascular disease risk factors: Korean National Health and Nutrition Examination Survey 2010","volume":"22","author":"Park JK","year":"2013","unstructured":"Park JK, Lim YH, Kim KS, et al.. Body fat distribution after menopause and cardiovascular disease risk factors: Korean National Health and Nutrition Examination Survey 2010. J Womens Health (Larchmt). 2013, 22:587-94. 10.1089\/jwh.2012.4035","journal-title":"J Womens Health (Larchmt)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050711","article-title":"Relationship between osteoporosis and cardiovascular disease in postmenopausal women","volume":"20","author":"Tank\u00f3 LB","year":"2005","unstructured":"Tank\u00f3 LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005, 20:1912-20. 10.1359\/JBMR.050711","journal-title":"J Bone Miner Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2011.13260","article-title":"Calcium supplementation, osteoporosis and cardiovascular disease","volume":"141","author":"Meier C","year":"2011","unstructured":"Meier C, Kr\u00e4nzlin ME. Calcium supplementation, osteoporosis and cardiovascular disease. Swiss Med Wkly. 2011, 141:w13260. 10.4414\/smw.2011.13260","journal-title":"Swiss Med Wkly"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.09.083","article-title":"Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis","volume":"97","author":"Ensrud K","year":"2006","unstructured":"Ensrud K, Genazzani AR, Geiger MJ, et al.. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol. 2006, 97:520-7. 10.1016\/j.amjcard.2005.09.083","journal-title":"Am J Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jch.13010","article-title":"Calcium supplementation and cardiovascular risk: a rising concern","volume":"19","author":"Tankeu AT","year":"2017","unstructured":"Tankeu AT, Ndip Agbor V, Noubiap JJ. Calcium supplementation and cardiovascular risk: a rising concern. J Clin Hypertens (Greenwich). 2017, 19:640-6. 10.1111\/jch.13010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.116.148171","article-title":"Dietary calcium intake and risk of cardiovascular disease, stroke, and fracture in a population with low calcium intake","volume":"106","author":"Kong SH","year":"2017","unstructured":"Kong SH, Kim JH, Hong AR, Cho NH, Shin CS. Dietary calcium intake and risk of cardiovascular disease, stroke, and fracture in a population with low calcium intake. Am J Clin Nutr. 2017, 106:27-34. 10.3945\/ajcn.116.148171","journal-title":"Am J Clin Nutr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30346-8","article-title":"Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT extension study","volume":"7","author":"McClung MR","year":"2019","unstructured":"McClung MR, O'Donoghue ML, Papapoulos SE, et al.. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT extension study. Lancet Diabetes Endocrinol. 2019, 7:899-911. 10.1016\/S2213-8587(19)30346-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13869","article-title":"Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis","volume":"85","author":"Stone JA","year":"2019","unstructured":"Stone JA, McCrea JB, Witter R, Zajic S, Stoch SA. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis. Br J Clin Pharmacol. 2019, 85:1072-83. 10.1111\/bcp.13869","journal-title":"Br J Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2217\/whe.15.39","article-title":"Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis","volume":"11","author":"Schultz TC","year":"2015","unstructured":"Schultz TC, Valenzano JP, Verzella JL, Umland EM. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis. Womens Health (Lond). 2015, 11:805-14. 10.2217\/whe.15.39","journal-title":"Womens Health (Lond)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12339","article-title":"Efficacy, effectiveness and side effects of medications used to prevent fractures","volume":"277","author":"Reid IR","year":"2015","unstructured":"Reid IR. Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med. 2015, 277:690-706. 10.1111\/joim.12339","journal-title":"J Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2013.12.011","article-title":"Use of SERMs for treatment in postmenopausal women","volume":"142","author":"Pinkerton JV","year":"2014","unstructured":"Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol. 2014, 142:142-54. 10.1016\/j.jsbmb.2013.12.011","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.7.847","article-title":"Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial","volume":"287","author":"Barrett-Connor E","year":"2002","unstructured":"Barrett-Connor E, Grady D, Sashegyi A, et al.. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002, 287:847-57. 10.1001\/jama.287.7.847","journal-title":"JAMA"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor E","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, et al.. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006, 355:125-37. 10.1056\/NEJMoa062462","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003815","article-title":"Calcium intake from diet and supplements and the risk of coronary artery calcification and its progression among older adults: 10-year follow-up of the multi-ethnic study of atherosclerosis (MESA)","volume":"5","author":"Anderson JJ","year":"2016","unstructured":"Anderson JJ, Kruszka B, Delaney JA, et al.. Calcium intake from diet and supplements and the risk of coronary artery calcification and its progression among older adults: 10-year follow-up of the multi-ethnic study of atherosclerosis (MESA). J Am Heart Assoc. 2016, 5:e003815. 10.1161\/JAHA.116.003815","journal-title":"J Am Heart Assoc"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(04)15544-x","article-title":"Coronary calcification score: the coronary-risk impact factor","volume":"363","author":"Thompson GR","year":"2004","unstructured":"Thompson GR, Partridge J. Coronary calcification score: the coronary-risk impact factor. Lancet. 2004, 363:557-559. 10.1016\/s0140-6736(04)15544-x","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1636","article-title":"Risk of myocardial infarction among new users of calcium supplements alone or combined with vitamin D: a population-based case-control study","volume":"107","author":"Rodr\u00edguez-Mart\u00edn S","year":"2020","unstructured":"Rodr\u00edguez-Mart\u00edn S, Gonz\u00e1lez-Bermejo D, Rodr\u00edguez-Miguel A, et al.. Risk of myocardial infarction among new users of calcium supplements alone or combined with vitamin D: a population-based case-control study. Clin Pharmacol Ther. 2020, 107:359-68. 10.1002\/cpt.1636","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/73772-osteoporosis-prevention-and-treatment-the-risk-of-comorbid-cardiovascular-events-in-postmenopausal-women","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:48Z","timestamp":1707507408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/73772-osteoporosis-prevention-and-treatment-the-risk-of-comorbid-cardiovascular-events-in-postmenopausal-women"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.24117","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,13]]}}}